Neuren Pharmaceuticals Limited (ASX:NEU) introduced its first ongoing Dividend program in H1 2026 as growing DAYBUE royalties provided a larger recurring source of cash flow. The company declared a fully franked Interim Dividend of 15 cents per share even as reported profit declined due largely to increased Investment in NNZ-2591 development. The new policy therefore links Shareholder distributions more directly to Royalty income rather than accounting profit alone.

First Dividend Program Begins

Neuren announced its first-ever dividend program alongside its H1 2026 results.

The company declared a fully franked interim dividend of 15 cents per share, representing a total distribution of approximately A$19 million.

The dividend was paid on 7 October 2026.

Under the new policy, Neuren intends to distribute between 70% and 100% of an Available Pool calculated from after-tax royalty income after corporate and administration costs.

The H1 dividend represented a payout of approximately 90% of that Available Pool.

DAYBUE Royalties Continue to Increase

DAYBUE royalty income reached US$23.3 million in H1 2026, an increase of 29% from the prior corresponding period.

In Australian-dollar terms, royalty income was A$33.2 million.

DAYBUE net sales reached US$226 million during the half, up 25% from H1 2025.

The increase was supported by continued adoption in the United States, including uptake of the DAYBUE STIX powder formulation.

The growing royalty stream provides Neuren with recurring income without requiring it to fund DAYBUE’s commercial infrastructure directly.

Q2 Sales Set a New Record

DAYBUE recorded net sales of US$125 million during the June 2026 quarter, up approximately 30% from the prior corresponding period.

Neuren earned Q2 royalty income of US$12.9 million.

Following the quarterly result, full-year 2026 DAYBUE sales guidance was increased to US$480 million to US$510 million.

This implied full-year royalty income for Neuren of approximately US$52.6 million to US$56.2 million based on the company’s assumptions.

Higher sales therefore provide additional support for the new dividend framework while funding Neuren’s internal development pipeline.

Profit Falls as R&D Spending Rises

Total H1 2026 Revenue increased 8% to A$42.7 million from A$39.7 million.

However, profit after tax declined to A$4.9 million from A$15.0 million in H1 2025.

Research and development expenditure increased to A$27.4 million from A$14.9 million, reflecting the progression of the NNZ-2591 clinical program.

Basic earnings per share declined to 3.83 cents from 11.88 cents.

The dividend therefore exceeded reported half-year earnings per share, reflecting the company’s decision to base distributions primarily on after-tax royalty cash generation rather than statutory earnings.

Balance Sheet Remains Well Funded

At 30 June 2026, Neuren held A$26.9 million in cash and cash equivalents and A$259.6 million in short-term investments.

Combined cash and short-term investments therefore totalled approximately A$286.5 million.

The company has stated that its current development programs remain fully funded.

During H1 2026, Neuren also repurchased 315,550 shares for approximately A$3.9 million at an average price of A$12.29 per share.

The Balance Sheet provides capacity to fund clinical development alongside the new dividend program.

European Approval Expands DAYBUE's Reach

DAYBUE reached another regulatory milestone in August 2026 when the European Commission granted Marketing authorisation for trofinetide for Rett syndrome.

This followed the positive regulatory opinion received earlier in the year.

A commercial launch in Germany was expected in early Q4 2026, representing the next stage of DAYBUE’s expansion beyond North America.

Neuren is eligible for royalties and milestone payments from international DAYBUE sales under its licensing agreement.

European commercialisation could therefore broaden the royalty base beyond the existing US-led contribution.

Japan Remains Another Potential Market

A clinical study of trofinetide is also under way in Japan to support a potential marketing application.

Topline results were expected between September and November 2026, with a regulatory submission anticipated during 2027 if development progresses as planned.

Japan represents another potential source of milestone and royalty income for Neuren.

Progress in Europe and Japan may gradually reduce the company’s reliance on US DAYBUE sales, although international commercial adoption remains uncertain.

NNZ-2591 Drives Internal Development Spending

Neuren’s main internally controlled development asset is NNZ-2591.

The Koala Phase 3 trial is evaluating NNZ-2591 in children with Phelan-McDermid syndrome.

The study is expected to enrol approximately 160 children and is supported by a 52-week open-label extension.

Neuren has indicated that total expected costs for the Phelan-McDermid development program remain within its previously stated US$80 million to US$90 million range.

The company is also progressing NNZ-2591 across other neurodevelopmental disorders.

Key Risks and Areas to Watch

Neuren remains highly dependent on DAYBUE royalties for commercial revenue.

Changes in patient uptake, pricing, competition or reimbursement could therefore materially affect cash flow.

Clinical development also carries uncertainty, particularly as the NNZ-2591 program advances through Phase 3 testing.

Higher research spending may continue to suppress statutory earnings even if royalty revenue increases.

Currency movements also affect the Australian-dollar value of US-dollar royalties.

The sustainability of the new dividend will therefore depend primarily on DAYBUE royalty growth, development spending and the board’s payout decisions under the new policy.